Cortical Circuitry and Synaptic Dysfunctions in Alzheimer’s Disease and Other DementiasView this Special Issue
Research Article | Open Access
Yuxia Li, Meimei Kang, Can Sheng, Guanqun Chen, Taoran Li, Jun Wang, Yanning Cai, Rong Wang, Ying Han, "Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population", Neural Plasticity, vol. 2020, Article ID 9742138, 10 pages, 2020. https://doi.org/10.1155/2020/9742138
Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population
We investigated the relationship between urinary Alzheimer-associated neuronal thread protein (AD7c-NTP) levels and apolipoprotein epsilon 4 (ApoE ɛ4) alleles, as well as other factors that cause cognitive decline, in the cognitively normal population. We recruited 329 cognitively normal right-handed Han Chinese subjects who completed ApoE gene testing and urinary AD7c-NTP testing. There was no significant difference in urinary AD7c-NTP levels between the normal control and subjective cognitive decline groups. Urinary AD7c-NTP levels were significantly higher in subjects with ApoE ɛ3/4 and 4/4 [0.6074 (0.6541) ng/mL] than in subjects without ApoE ɛ4 [0.4368 (0.3392) ng/mL and 0.5287 (0.3656) ng/mL], and urinary AD7c-NTP levels positively correlated with ApoE genotype grade (, ). There were significant differences in urinary AD7c-NTP levels between subjects with and without a history of coronary heart disease or diabetes. Urinary AD7c-NTP levels were not related to years of education, nature of work, family history of dementia, a history of hypertension, stroke, anemia, or thyroid dysfunction. Urinary AD7c-NTP levels were positively correlated with ApoE grade in the cognitively normal population. The relationship between risk factors of cognitive decline and urinary AD7c-NTP levels provides a new way for us to understand AD and urinary AD7c-NTP.
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60%–80% of all dementia, and imposes a substantial socioeconomic burden on society and families [1–4]. Furthermore, AD is an irreversible, disabling degenerative disease of the central nervous system. In the absence of curative treatments once the disease has progressed to AD dementia, primary prevention and early diagnosis in the preclinical stage of AD have been the main research focuses in recent years . It is therefore crucial to explore early biomarkers of AD to enable the early diagnosis of this disease, with the ultimate aim of treating and preventing dementia in preclinical AD.
Urinary AD7c-NTP, a peripheral biomarker for AD, is increased in mild cognitive impairment (MCI) and AD [6–9]. Previous studies have reported that AD7c-NTP immunoreactivity colocalizes with neurofibrillary tangles and dystrophic neurites, and increased AD7c-NTP levels are associated with tau-immunoreactive neurofibrillary tangles . Furthermore, overexpression of AD7c-NTP is associated with neurite sprouting and cell death, which is reflected in AD neurodegeneration . Recent research suggests that urinary AD7c-NTP is increased in hypertensive patients with cognitive impairment . In addition, a previous study reported that urinary AD7c-NTP is elevated in late-life depression with cognitive impairment . Furthermore, existing research recognizes that urinary AD7c-NTP has a critical role in cognitive decline, but not in depression or other diseases [12–15]. Urinary AD7c-NTP testing is noninvasive, radiation-free, repeatable, and easy to carry out. Therefore, urinary AD7c-NTP may be a promising peripheral biomarker for detecting cognitive decline and disease progression . Although previous studies have reported that cognitive decline is associated with elevated urinary AD7c-NTP, it is not clear which factors, aside from decreased cognitive function, are associated with elevated urinary AD7c-NTP [13, 15, 17, 18]. It has not been reported whether other medical history factors that may lead to a decline in cognitive function, such as carbon monoxide poisoning (COP), general anesthesia, or thyroid dysfunction, are associated with urinary AD7c-NTP levels in the normal cognitive population.
Subjective cognitive decline (SCD) refers to self-experienced persistent cognitive decline compared with a previously normal status, while standardized cognitive tests give objectively normal results [19, 20]. SCD is considered to be a preclinical phase of AD in patients who are objectively cognitively normal [21, 22]. Approximately 14.1% of SCD patients convert to AD within 4 years . SCD-plus, proposed by the Subjective Cognitive Decline Initiative, is considered closer to the early stage of AD [20, 23]. The conversion rate for SCD-plus to MCI is 18.9% . Therefore, both early diagnosis of AD and monitoring of progression in the SCD stage are essential for the early prevention and treatment of AD.
The apolipoprotein E epsilon 4 (ApoE ɛ4) allele is considered to be a risk factor for AD, and ApoE ɛ4 may influence the rate of cognitive decline in early AD . Clinical studies and autopsies have demonstrated that people with heterozygous ApoE ɛ4 are three times more likely to develop AD than noncarriers (), and people with a homozygous genotype of ApoE ɛ4/4 are 14 times more likely to develop AD () . ApoE ɛ4 carriers have lower concentrations of Aβ1–42, higher total tau and phosphorylated-tau, and a higher degree of brain atrophy than individuals without ApoE ɛ4 allele . ApoE is thought to be involved in plaque formation, and this idea is supported by the finding that ApoE is involved in the deposition or clearance of Aβ by direct protein-to-protein interaction [27, 28]. We know that increased urinary AD7c-NTP levels are associated with tau-immunoreactive neurofibrillary tangles and amyloid-β (Aβ) deposition; similarly, the ApoE allele is also associated with hyperphosphorylated tau and Aβ deposition, which are the pathological hallmarks of AD [10, 27, 29, 30]. However, the relationship between the two biomarkers remains unclear. Assuming that these two biomarkers are highly consistent and can reflect the risk of disease development, it may be beneficial to monitor the progression of AD using urinary AD7c-NTP as a noninvasive biomarker. Therefore, this study investigated the correlation between urinary AD7c-NTP and ApoE genotype and explored whether urinary AD7c-NTP is affected by other factors that may lead to cognitive decline, further demonstrating the feasibility of urinary AD7c-NTP as a biomarker of AD.
2. Materials and Methods
This study is part of the Sino Longitudinal Study on Cognitive Decline (SILCODE) . The study was approved by the Xuanwu Hospital Research Ethics Review Committee (ClinicalTrials.gov identifier: NCT03370744), and all participants signed their informed consent. A total of 329 cognitively normal right-handed Han Chinese subjects participated in the study, of which 151 were diagnosed with SCD and 178 were used as the cognitively normal controls (NC). All subjects were recruited through standardized public advertisements or memory clinics. SCD diagnosis was carried out by two experienced neurologists in the Department of Neurology, Xuanwu Hospital, Capital Medical University, based on the SCD-plus diagnostic framework of the Subjective Cognitive Decline Initiative [20, 23]. The inclusion criteria for SCD included Han Chinese nationality; right-handedness; older than 60 years; decline in memory as the primary symptom, rather than in any other cognitive domain; sustained cognitive decline in self-perception, independent of acute events, as compared with the previous healthy state; continuous concerns or worries associated with memory loss; cognitive function reported to be worse than that of others in the same age group; memory loss certified by an informed person; subject failed to meet the criteria for MCI or AD [32, 33].
The NCs were recruited from local communities through broadcast and online media advertising. The inclusion criteria for NC included Han Chinese nationality; right-handedness; older than 60 years; no memory or other cognitive decline complaints, with no concerns or worries about their cognition; normal scores in standardized neuropsychological tests, scale-adjusted for sex, age, and education; negative result for nervous system physical examinations; without any relevant medical histories or family histories; and accessory examinations revealed no diseases that could cause cognitive decline . The exclusion criteria for all participants included congenital and acquired severe cognitive decline, MCI, AD, vascular cognitive dysfunction, or other dementia; a history of stroke, severe psychiatric disease, Parkinson’s disease, multiple sclerosis, or brain tumor; alcohol or drug abuse; syphilis or acquired immune deficiency syndrome; severe liver and kidney dysfunction; severe hearing or visual impairment; and failure to cooperate with the study protocol.
2.2. Neuropsychological Assessment and Laboratory Measurements
All subjects underwent detailed medical history inquiries, neurological examinations, and medical system examinations and completed a neuropsychological assessment for diagnosis and differential diagnosis. Medical history collection included detailed inquiries about previous hypertension, diabetes, coronary heart disease, stroke, anemia, abnormal thyroid function, history of surgery under general anesthesia, history of COP, history of head trauma, and family history of dementia. Neuropsychological assessment scales included the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment-Basic (MoCA-B), Animal Verbal Fluency Test, Boston Naming Test (30 items), Auditory Verbal Learning Test-HuaShan (AVLT-H), Shape Trails (test A and test B), 17-item Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Scale (HAMA), and Functional Activities Questionnaire (FAQ). MMSE were considered normal for subjects with more than 6 years of education, while MMSE were considered normal for subjects with 1–6 years of education. When the subject was illiterate, an MMSE was considered normal . MoCA-B scores were considered normal when they were for the subjects with 0–6 years of education, >22 for those with 7–12 years of education, and>24 for those with 13 or more years of education .
All participants had blood samples collected in the morning after 8 hours with no food or water. Laboratory tests included a routine blood test, routine urine test, blood biochemistry, homocysteine, activated partial thromboplastin time, antibody tests for syphilis and human immunodeficiency virus, thyroid series, serum folic acid test, and serum vitamin B12 test, which were used to exclude other diseases that may lead to memory loss. ApoE gene testing was performed on all the subjects by Professor Yanning Cai. ApoE genotyping was performed by sequencing codons 112 and 158 of exon 4 of the ApoE gene .
2.3. Urinary AD7c-NTP Laboratory Detection
The levels of AD7c-NTP in urine samples were measured using the enzyme-linked immunosorbent assay AD7c-NTP kit (Anqun Biological Technology Co. Ltd., Shenzhen, China). All subjects collected clean midstream urine samples in the morning and placed them in Eppendorf tubes containing boric acid (2 g/L) as a preservative. Samples were centrifuged immediately and stored in a refrigerator at 4°C. The urine samples were observed visually. If the urine was cloudy or dark, it was discarded, and urine samples were collected the next morning. According to the manufacturer’s instructions, the concentrated washing solution was diluted with distilled water at a ratio of 1 : 25. First, approximately 100 μL of the sample was added, and the solution was incubated at 37°C for 60 min. The sample was then removed, the liquid on the plate was shaken off, and five consecutive wash steps were performed using phosphate-buffered saline (PBS) before the sample was patted dry. Next, 100 μL of biotinylated rabbit anti-AD7c-NTP antibody was added and incubated at 37°C for 30 min. The reaction plate was removed, washed thoroughly with PBS, and patted dry. Next, 100 μL of horseradish peroxidase-labeled avidin was added to the reaction plate, which was then sealed and incubated at 37°C for 30 min. After washing five times with PBS, 50 μL of chromogenic reagents A and B were added in turn, mixed well, and incubated at 37°C for 15 min. Finally, the reaction was stopped by adding 50 μL of sulfuric acid as the stop buffer and mixing well. A microplate reader was used to measure the absorbance (A value) at 450 nm wavelength, and the AD7c-NTP concentration was calculated according to the formula.
2.4. Classification of Demographic Characteristics and Blood ApoE Genotype
Education levels were grouped by high school level and divided into less than 12 years, 12 years, and more than 12 years of education. The nature of each subject’s employment was classified into manual labor, mental labor, or mixed labor.
Previous clinical- or autopsy-based studies reported that AD risk is increased in people with genotypes ApoE ɛ2/4, ApoE ɛ3/4, and ApoE ɛ4/4; in contrast, AD risk is decreased in people with genotypes ApoE ɛ2/2 and ApoE ɛ2/3 . Based on this information, all subjects were divided into four groups according to their genotype. Grade 1 included genotypes ApoE ɛ2/2 and ApoE ɛ2/3 (the risk of AD is reduced with these two genotypes, for each), grade 2 was made up of the genotype ApoE ɛ3/3 (this genotype neither increases nor decreases the risk of AD), grade 3 included the ApoE ɛ2/4 genotype (this genotype confers a mildly elevated risk of AD; ), and grade 4 was made up of the genotypes ApoE ɛ3/4 and ApoE ɛ4/4 (these genotypes confer a significantly increased risk of AD; and ; Table 1).
Key: CHD: history of coronary heart disease; COP: carbon monoxide poisoning; FHD: family history of dementia; SCD: subjective cognitive decline; NC: normal controls.
History of coronary heart disease (CHD) verified by medical documents and the diagnosis was based on the 2013 ESC guidelines for the diagnosis and management of stable coronary artery disease . A diagnosis of diabetes was based on the American Diabetes Association criteria for elevated fasting blood glucose (≥7.0 mmol/L or ≥126 mg/dL) for patients with a history of diabetes . Hypertension was defined as a clinical history of hypertension for more than 1 year, excluded secondary hypertension . A history of stroke was defined as a history of cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage and was certified by medical documents. Anemia was defined as hemoglobin below 120 g/L in men and 110 g/L in women. A history of hyperthyroidism and hypothyroidism, COP, general anesthesia, and head trauma, and a family history of dementia (FHD), were all self-reported and verified using medical or hospital records. Subjects with these histories were assigned to the positive group (+), while subjects without these histories were assigned to the negative group (–).
2.5. Statistical Analysis
All data were analyzed using the Statistical Package for Social Sciences (SPSS) v22.0 software. Data with continuous variables were expressed as the (SD). Data for discontinuous variables were expressed as the median (interquartile range). Counting data were analyzed using the chi-square test. The two-independent-sample -test was adopted to compare data between two groups, and the analysis of variance (ANOVA) was used to compare data among three or four groups. The Mann–Whitney test was used to compare data for discontinuous variables, while the Kruskal–Wallis test for multiple comparisons was used for discontinuous variables. Further, Spearman correlation analysis was used to analyze the correlation between ApoE allele and urinary AD7c-NTP levels. A threshold of was considered statistically significant.
3.1. Participant Demographic Data
We recruited 329 right-handed Han Chinese subjects with an average age of years; 30.7% () of the subjects were male (Table 1). Disease prevalence, including the prevalence of CHD, diabetes, hypertension, stroke, anemia, and thyroid dysfunction, is recorded in Table 1. Past medical history, such as COP, general anesthesia, head trauma, and family history of dementia, is also shown in Table 1. Personal history data, including years in education and nature of work, are shown in Table 1, and subjects were grouped according to their personal history or past medical history. ApoE genotype was detected and consisted of ApoE ɛ2/2 (2 subjects), ApoE ɛ2/3 (38 subjects), ApoE ɛ3/3 (208 subjects), ApoE ɛ2/4 (11 subjects), ApoE ɛ3/4 (68 subjects), and ApoE ɛ4/4 (2 subjects). The subjects were divided into four groups based on ApoE genotype (Table 1).
3.2. Urinary AD7c-NTP Levels by Years of Education and Nature of Work
According to the Kruskal–Wallis test, there were no significant differences in urinary AD7c-NTP levels among subjects with different years of education or nature of work (, Table 2).
Key: AD7c-NTP: Alzheimer-associated neuronal thread protein; CHD: history of coronary heart disease; COP: carbon monoxide poisoning; FHD: family history of dementia; SCD: subjective cognitive decline; NC: normal controls; Data in AD7c-NTP were shown in median (interquartile range).
3.3. Urinary AD7c-NTP Levels by Past Medical History and Family History of Dementia
In Table 2, there was a significant difference in urinary AD7c-NTP levels between subjects with a history of CHD and subjects without a history of this disease (, ). There was also a significant difference in urinary AD7c-NTP levels between subjects with and without a history of diabetes (, ). According to the Mann–Whitney test, there were no significant differences in urinary AD7c-NTP levels in subjects with a family history of dementia or other medical histories such as hypertension, stroke, anemia, thyroid dysfunction, COP, general anesthesia, or head trauma (, Table 2).
3.4. Urinary AD7c-NTP Levels by SCD Diagnosis and ApoE Genotype
There was no significant difference in urinary AD7c-NTP levels between the NC [0.5164 (0.3667) ng/mL] and SCD [0.5483 (0.4838) ng/mL] groups (, Table 2). The Kruskal–Wallis test revealed that there were significant differences in urinary AD7c-NTP levels among subjects with different ApoE genotypes (, , Table 2). Furthermore, urinary AD7c-NTP levels in subjects with ApoE ɛ3/4 and ApoE ɛ4/4 were significantly higher [0.6074 (0.6541) ng/mL] than in subjects without ApoE ɛ4 [0.4368 (0.3392) ng/mL and 0.5287 (0.3656) ng/mL].
Moreover, Spearman correlation analysis revealed that urinary AD7c-NTP levels were positively correlated with ApoE grade; that is, urinary AD7c-NTP levels increased with increased ApoE grade (, , Figure 1).
The present study was designed to investigate the relationship between urinary AD7c-NTP levels and ApoE ɛ4 alleles, as well as with other factors associated with cognitive decline in the cognitively normal population. Our study revealed that (i) urinary AD7c-NTP levels were not significantly different among subjects with different years of education and nature of work; (ii) there were significant differences in urinary AD7c-NTP between subjects with and without a history of CHD or diabetes; (iii) urinary AD7c-NTP levels were not significantly different in people with a family history of dementia or a history of hypertension, stroke, anemia, or thyroid dysfunction; and (iv) urinary AD7c-NTP levels in subjects with ApoE ɛ4 were significantly higher than in subjects without ApoE ɛ4, and urinary AD7c-NTP levels increased with an increase in ApoE grade.
4.1. The Relationship between Urinary AD7c-NTP Levels, Personal History, and SCD Diagnosis
In the present study, urinary AD7c-NTP levels were not significantly different among subjects with different years of education or nature of work. These findings are in line with other reports that urinary AD7c-NTP is not affected by demographic factors or common chronic diseases . Previous evidence suggests that being married and living in an urban environment can decrease the risk of cognitive impairment . In the current study, although urinary AD7c-NTP levels were not increased in subjects with fewer years of education or who had worked in manual labor, the speed of cognitive decline affected by cognitive reserve remains a focus for neurologists.
In the present study, it was revealed that the levels of urinary AD7c-NTP were not higher in SCD patients compared with the NC group. This result is consistent with previous results from our research group . The reason for these results may be that SCD is still a very early stage of the disease when neuropsychological test scores are normal; thus, tau protein may not be increased or detected at this stage . Findings from the DELCODE study included a decline in memory and language in SCD, and SCD-plus features were associated with lower Aβ42 and a lower Aβ42/tau ratio but were not associated with total tau or p-tau-181 levels . Furthermore, the DELCODE study reported lower CSF-Aβ42 levels and lower CSF-Aβ42/tau ratios in SCD patients than in healthy controls, while total tau and p-tau-181 levels were not elevated in the SCD group . Urinary AD7c-NTP levels are a good indicator of tau protein levels; there is no increase in tau in SCD, and this evidence further supports our result of normal urinary AD7c-NTP levels in SCD patients. Urinary AD7c-NTP is a promising biomarker for AD, and its level is proportional to the degree of dementia . SCD is still in the preclinical AD stage, without objective evidence of cognitive impairment, and this may be one of the reasons why urinary AD7c-NTP was not elevated in subjects with SCD.
4.2. The Relationship between Urinary AD7c-NTP Levels and Family History of Dementia or Past Medical History
Previous studies have reported that a family history of dementia increases the risk of developing dementia [44, 45]. In the current study, urinary AD7c-NTP levels were not different in people with or without a family history of dementia. This result suggests that a family history of dementia does not increase urinary AD7c-NTP levels. This may be because urinary AD7c-NTP is an indicator of tau, and there may not be any abnormal increase in tau in these subjects with a family history of dementia.
Another important finding was that urinary AD7c-NTP levels were elevated in people with a history of CHD and diabetes. CHD and diabetes are both risk factors for AD and dementia [40, 46]. Previous research has demonstrated that cholesterol metabolic disorder is a common cause and risk factor of CHD and AD . There is evidence that ApoE ɛ4 alleles and hyperlipidemia play a crucial role in the relationship between AD and CHD. Hyperlipidemia could aggravate coronary atherosclerosis and damage the blood–brain barrier, as well as promote Aβ protein production and tau deposition in the brain . Diabetes increases the risk of AD by affecting glucose transmission to the brain and reducing glucose metabolism. It has been reported that glucose/lipid metabolism, oxidative stress, mitochondrial dysfunction, and protein changes in metabolic disorders caused by diabetes can all increase the prevalence of AD by promoting pathological changes in Aβ in diabetic patients . Our results from the present study suggest that urinary AD7c-NTP is elevated in subjects with AD risk factors, and that urinary AD7c-NTP may therefore be a peripheral biomarker to predict AD risk factors.
Urinary AD7c-NTP levels were not elevated in people with a medical history of hypertension, stroke, anemia, or thyroid dysfunction in the current study. This result is also in accordance with earlier observations by our team, which revealed that urinary AD7c-NTP levels were not affected by common chronic diseases such as hypertension, stroke, dyslipidemia, renal insufficiency, cancer, chronic lung disease, chronic liver disease, or symptoms of depression . The present study differs from the previous one in that we chose different diseases, but they are all chronic diseases that may cause cognitive decline. Hypertension and stroke are known risk factors for AD and dementia [40, 46]. A recent study reported that urinary AD7c-NTP is increased in hypertensive patients with cognitive decline; in contrast, the subjects in our study were from a population with a high risk of AD, but with normal cognition . In our study, subjects with hypertension and normal cognition did not show elevated urinary AD7c-NTP. Anemia and high levels of hemoglobin are associated with an increased risk of AD . Recent evidence suggests that hypothyroidism and hyperthyroidism are associated with AD, and hypothyroidism or hyperthyroidism may be one cause of cognitive impairment, including AD . Although these diseases may increase the risk of cognitive decline, there is little evidence that these diseases are associated with increased tau protein. This may help to explain why there was no increase in urinary AD7c-NTP levels in subjects with a history of these diseases in the current study. COP, general anesthesia, and head trauma may also contribute to cognitive decline [51–53]. Cognitive impairment after COP is thought to be related to delayed encephalopathy caused by carbon monoxide, which is a symptom of frontal lobe dysfunction [51, 54]. A recent study reported that major surgery is associated with a small amount of long-term cognitive decline: cognitive decline after surgery was approximately double the level that it was before surgery . Some studies have also demonstrated that about half of all patients with mild traumatic brain injury had long-term cognitive impairment and cognitive decline, including in learning and memory, attention, executive function, and processing speed . Nevertheless, none of these causes of cognitive impairment involve neurodegeneration. Thus, in our study, we did not find elevated urinary AD7c-NTP levels in subjects with a history of COP, general anesthesia, or head trauma.
4.3. The Relationship between Urinary AD7c-NTP Levels and ApoE Genotype
The most important finding to emerge from the present analysis was that urinary AD7c-NTP levels were significantly higher in subjects with ApoE ɛ4 genotypes than in subjects without ApoE ɛ4 genotypes and that urinary AD7c-NTP levels increased with increased ApoE grade. This finding is consistent with that of previous studies , which have shown that urinary AD7c-NTP levels are elevated in MCI patients with ApoE ɛ4 alleles .
Carrying the ApoE ɛ4 allele is considered to be the primary genetic risk factor for sporadic AD . Previous studies have confirmed that ApoE ɛ4 prevalence is 51% in the cognitively normal population, 64% in patients with mild cognitive impairment, and 66% in patients with AD . In particular, ApoE ɛ4 carriers are more likely to develop AD at an earlier age than those without an ApoE ɛ4 allele . Previous studies have reported that heterozygous ApoE ɛ4 carriers shift the risk curve to develop the disease 5 years earlier, while homozygous ApoE ɛ4/4 carriers shift it to develop the disease 10 years earlier, and ApoE ɛ2 carriers shift it to develop the disease 5 years later [59, 60]. Furthermore, evidence has revealed that ApoE influences Aβ deposition in a dose- and isoform-specific fashion () . Therefore, in this study, we ranked the ApoE alleles according to their AD risk.
Urinary AD7c-NTP levels were higher in subjects with ApoE ɛ4 than in subjects without ApoE ɛ4 in the present study. This result may be because both ApoE and urinary AD7c-NTP are related to tau and Aβ deposition. Substantial evidence suggests that the ApoE ɛ4 allele is related to increased Aβ deposition, rapid thinning of the cortex, and accelerated cognitive decline, while the ApoE ɛ2 allele is related to a decrease in Aβ deposits, slower thinning of the cortex, and slower cognitive decline [62–65]. Reports from experiments on animals show that the ApoE ɛ4 allele disrupts memory function in rodents, and further studies have indicated that fragments of the ApoE ɛ4 allele may contribute to both plaque and tangle formation . It has been demonstrated that the ApoE genotype can affect tau neuropathological changes in AD patients . In the current study, there was a positive correlation between urinary AD7c-NTP levels and ApoE grades. There is evidence that ApoE ε4 is associated with a higher density of paired helical filament tau tangles, while ApoE ε2 is associated with fewer paired helical filament tau tangles in AD patients with Aβ . In addition, experiments on animals have shown that the ApoE allele affects tau pathogenesis and tau-mediated neurodegeneration .
ApoE allele and urinary AD7c-NTP levels are both promising biomarkers of AD. Previous studies have shown that the combined detection of ApoE ε4 and urinary AD7c-NTP is a reliable biomarker for the early diagnosis of AD and that the predictive value is significantly increased compared with the detection of either one individually [56, 68]. The high consistency of these two biomarkers also provides a new way for us to understand and think about AD. The combination of two biomarkers may help the early diagnosis of AD and improve the diagnostic accuracy of AD and be better than one biomarker alone.
There are, however, some limitations to this study. First, subjects with normal cognition were recruited, and the correlation between urinary AD7c-NTP levels and ApoE allele in patients with abnormal cognition, such as with MCI or AD, should be further analyzed. Second, because of the low incidence of ApoE ɛ2/4 in the population, this study included only 11 subjects with ApoE ɛ2/4 out of 329 cognitively normal subjects; this genotype was relatively rare compared with other genotypes. Third, a longitudinal, multicenter, large study is needed to observe dynamic changes in AD7c-NTP levels in urine.
There were significant differences in urinary AD7c-NTP levels between subjects with and without a history of CHD or diabetes. Urinary AD7c-NTP levels were positively correlated with ApoE grade in the cognitively normal population. The relationship between AD risk factors and urinary AD7c-NTP levels may provide a new way for us to understand AD and urinary AD7c-NTP.
The data used to support the findings of the present research are available from the corresponding authors once requested.
Conflicts of Interest
There is no conflict of interest.
This article was supported by the National Key Research and Development Program of China (2016YFC1306302, 2018YFC1312001, 2018YFA0108503), the National Natural Science Foundation of China (Grant 61633018, 81801052), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201706), the Beijing Municipal Commission of Health and Family Planning (PXM2020_026283_000002), the China Postdoctoral Science Foundation (2018M641414), the Beijing Postdoctoral Research Foundation (ZZ2019-12), and the Xuanwu Hospital, Capital Medical University (No. XWJL-2019004).
- L. Jia, M. Quan, Y. Fu et al., “Dementia in China: epidemiology, clinical management, and research advances,” The Lancet Neurology, vol. 19, no. 1, pp. 81–92, 2020.
- J. Jia, C. Wei, S. Chen et al., “The cost of Alzheimer's disease in China and re-estimation of costs worldwide,” Alzheimers Dement, vol. 14, no. 4, pp. 483–491, 2018.
- J. Garre-Olmo, “Epidemiology of Alzheimer's disease and other dementias,” Revista de Neurologia, vol. 66, no. 11, pp. 377–386, 2018.
- B. Sabayan and F. Sorond, “Reducing Risk of Dementia in Older Age,” JAMA, vol. 317, no. 19, p. 2028, 2017.
- R. A. Armstrong, “Risk factors for Alzheimer's disease,” Folia Neuropathologica, vol. 57, no. 2, pp. 87–105, 2019.
- R. Wang, J. I. Zhijuan, S. Sheng et al., “Detection of urine neural thread protein for diagnosis of Alzheimer disease and its clinical significance,” Chinese Journal of Laboratory Medicine, vol. 33, no. 1, pp. 46–50, 2010.
- L. Ma, R. Wang, Y. Han et al., “Development of a novel urine Alzheimer-associated neuronal thread protein ELISA kit and its potential use in the diagnosis of Alzheimer's disease,” Journal of Clinical Laboratory Analysis, vol. 30, no. 4, pp. 308–314, 2016.
- L. Ma, J. Chen, R. Wang et al., “The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment,” Journal of Clinical Neuroscience, vol. 22, no. 4, pp. 649–652, 2015.
- B. D. Ku, H. Kim, Y. K. Kim, and H. U. Ryu, “Comparison of urinary Alzheimer-associated neural thread protein (AD7c-NTP) levels between patients with amnestic and nonamnestic mild cognitive impairment,” American Journal of Alzheimer's Disease & Other Dementias®, vol. 35, 2020.
- S. M. de la Monte, R. I. Carlson, N. V. Brown, and J. R. Wands, “Profiles of neuronal thread protein expression in Alzheimer's disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 10, pp. 1038–1050, 1996.
- S. M. Monte, K. Ghanbari, W. H. Frey et al., “Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid,” The Journal of Clinical Investigation, vol. 100, no. 12, pp. 3093–3104, 1997.
- Y. Zhang, Y. Li, R. Wang, G. Sha, H. Jin, and L. Ma, “Elevated urinary AD7c-NTP levels in older adults with hypertension and cognitive impairment,” Journal of Alzheimer's Disease, vol. 74, no. 1, pp. 237–244, 2020.
- Q. E. Zhang, S. Ling, P. Li et al., “The association between urinary Alzheimer-associated neuronal thread protein and cognitive impairment in late-life depression: a controlled pilot study,” International Journal of Biological Sciences, vol. 14, no. 11, pp. 1497–1502, 2018.
- H. Jin, S. Guan, R. Wang et al., “The distribution of urinary Alzheimer-associated neuronal thread protein and its association with common chronic diseases in the general population,” Journal of Alzheimer's Disease, vol. 65, no. 2, pp. 433–442, 2018.
- Y. Li, M. Kang, H. Wang et al., “Urinary Alzheimer-associated neuronal thread protein is not elevated in patients with subjective cognitive decline and patients with depressive state,” Journal of Alzheimer's Disease, vol. 71, no. 4, pp. 1115–1123, 2019.
- Y. C. Youn, K.-W. Park, S.-H. Han, and S. Y. Kim, “Urine neural thread protein measurements in Alzheimer disease,” Journal of the American Medical Directors Association, vol. 12, no. 5, pp. 372–376, 2011.
- Z. Rui, Y. Xin Rui, and P. Dan Tao, “Vallie of Alzheimer-associated neuronaI thread protein level in urine for diagnosing Ahheimer’s disease,” Chinese Journal of Geriatrics, vol. 31, no. 7, pp. 575–577, 2012.
- P. J. Kahle, M. Jakowec, S. J. Teipel et al., “Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF,” Neurology, vol. 54, no. 7, pp. 1498–1504, 2000.
- F. Jessen, R. E. Amariglio, R. F. Buckley et al., “The characterisation of subjective cognitive decline,” The Lancet Neurology, vol. 19, no. 3, pp. 271–278, 2020.
- F. Jessen, R. E. Amariglio, M. van Boxtel et al., “A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease,” Alzheimer's & Dementia, vol. 10, no. 6, pp. 844–852, 2014.
- A. J. Mitchell, H. Beaumont, D. Ferguson, M. Yadegarfar, and B. Stubbs, “Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis,” Acta Psychiatrica Scandinavica, vol. 130, no. 6, pp. 439–451, 2014.
- M. A. Fernández-Blázquez, M. Ávila-Villanueva, F. Maestú, and M. Medina, “Specific features of subjective cognitive decline predict faster conversion to mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 52, no. 1, pp. 271–281, 2016.
- J. L. Molinuevo, L. A. Rabin, R. Amariglio et al., “Implementation of subjective cognitive decline criteria in research studies,” Alzheimer's & Dementia, vol. 13, no. 3, pp. 296–311, 2017.
- S. Cosentino, N. Scarmeas, E. Helzner et al., “APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease,” Neurology, vol. 70, Issue 19, Part 2, pp. 1842–1849, 2008.
- L. A. Farrer, L. A. Cupples, J. L. Haines et al., “Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease,” JAMA, vol. 278, no. 16, pp. 1349–1356, 1997.
- V. Leoni, “The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 3, pp. 375–383, 2011.
- D. B. Carter, “The interaction of amyloid-β with ApoE,” Sub-Cellular Biochemistry, vol. 38, pp. 255–272, 2005.
- J. M. Riphagen, I. H. G. M. Ramakers, W. M. Freeze et al., “Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology,” Neurobiology of Aging, vol. 85, pp. 96–103, 2020.
- N. Zhang, L. Zhang, Y. Li et al., “Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer's disease and mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 60, no. 1, pp. 87–95, 2017.
- P. Scheltens, K. Blennow, M. M. B. Breteler et al., “Alzheimer's disease,” The Lancet, vol. 388, no. 10043, pp. 505–517, 2016.
- X. Li, X. Wang, L. Su, X. Hu, and Y. Han, “Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline,” BMJ Open, vol. 9, no. 7, article e028188, 2019.
- A. J. Jak, M. W. Bondi, L. Delano-Wood et al., “Quantification of five neuropsychological approaches to defining mild cognitive impairment,” The American Journal of Geriatric Psychiatry, vol. 17, no. 5, pp. 368–375, 2009.
- R. A. Sperling, P. S. Aisen, L. A. Beckett et al., “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimers Dement, vol. 7, no. 3, pp. 280–292, 2011.
- S. Xiao, “Application and value of neuropsychological test and rating scale in Alzheimer's disease,” Chinese Journal of Contemporary Neurology and Neurosurgery, vol. 5, no. 3, pp. 137–140, 2005.
- P. Julayanont, S. Tangwongchai, S. Hemrungrojn et al., “The montreal cognitive assessment-basic: a screening tool for mild cognitive impairment in illiterate and low-educated elderly adults,” Journal of the American Geriatrics Society, vol. 63, no. 12, pp. 2550–2554, 2015.
- P. A. Boyle, A. S. Buchman, R. S. Wilson, J. F. Kelly, and D. A. Bennett, “The APOE ε4 allele is associated with incident mild cognitive impairment among community-dwelling older persons,” Neuroepidemiology, vol. 34, no. 1, pp. 43–49, 2010.
- Task Force Members, G. Montalescot, U. Sechtem et al., “2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology,” European Heart Journal, vol. 34, no. 38, pp. 2949–3003, 2013.
- American Diabetes Association, “Standards of medical care in diabetes--2011,” Diabetes Care, vol. 34, Supplement 1, pp. S11–S61, 2010.
- A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 report,” JAMA, vol. 289, no. 19, pp. 2560–2572, 2003.
- S. Xiu, Q. Liao, L. Sun, and P. Chan, “Risk factors for cognitive impairment in older people with diabetes: a community-based study,” Therapeutic Advances in Endocrinology and Metabolism, vol. 10, 2019.
- M. Ávila-Villanueva and M. A. Fernández-Blázquez, “Subjective cognitive decline as a preclinical marker for Alzheimer's disease: the challenge of stability over time,” Frontiers in Aging Neuroscience, vol. 9, p. 377, 2017.
- L. Miebach, S. Wolfsgruber, A. Polcher et al., “Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study,” Alzheimer's Research & Therapy, vol. 11, no. 1, p. 66, 2019.
- S. Shi and J. Zhang, “A literature review of AD7c-ntp as a biomarker for Alzheimer’s disease,” Annals of Indian Academy of Neurology, vol. 16, no. 3, pp. 307–309, 2013.
- F. J. Wolters, S. J. van der Lee, P. J. Koudstaal et al., “Parental family history of dementia in relation to subclinical brain disease and dementia risk,” Neurology, vol. 88, no. 17, pp. 1642–1649, 2017.
- K. Sleegers, K. Bettens, A. De Roeck et al., “A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42,” Alzheimer's & Dementia, vol. 11, no. 12, pp. 1452–1460, 2015.
- M. V. F. Silva, C. de Mello Gomide Loures, L. C. V. Alves, L. C. de Souza, K. B. G. Borges, and M. das Graças Carvalho, “Alzheimer's disease: risk factors and potentially protective measures,” Journal of Biomedical Science, vol. 26, no. 1, p. 33, 2019.
- W. Chen, F. Jin, G. Cao et al., “ApoE4 may be a promising target for treatment of coronary heart disease and Alzheimer's disease,” Current Drug Targets, vol. 19, no. 9, pp. 1038–1044, 2018.
- Y. Sun, C. Ma, H. Sun et al., “Metabolism: a novel shared link between diabetes mellitus and Alzheimer's disease,” Journal of Diabetes Research, vol. 2020, Article ID 4981814, 12 pages, 2020.
- F. J. Wolters, H. I. Zonneveld, S. Licher et al., “Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI,” Neurology, vol. 93, no. 9, pp. e917–e926, 2019.
- K. Bavarsad, M. Hosseini, M.‐. A.‐. R. Hadjzadeh, and A. Sahebkar, “The effects of thyroid hormones on memory impairment and Alzheimer's disease,” Journal of Cellular Physiology, vol. 234, no. 9, pp. 14633–14640, 2019.
- K. Yanagiha, K. Ishii, and A. Tamaoka, “Acetylcholinesterase inhibitor treatment alleviated cognitive impairment caused by delayed encephalopathy due to carbon monoxide poisoning,” Medicine, vol. 96, no. 8, p. e6125, 2017.
- I. Urits, V. Orhurhu, M. Jones, D. Hoyt, A. Seats, and O. Viswanath, “Current perspectives on postoperative cognitive dysfunction in the ageing population,” Turkish Journal of Anaesthesiology and Reanimation, vol. 47, no. 6, pp. 439–447, 2019.
- K. McInnes, C. L. Friesen, D. E. MacKenzie, D. A. Westwood, and S. G. Boe, “Correction: Mild Traumatic Brain Injury (mTBI) and chronic cognitive impairment: a scoping review,” PLoS One, vol. 14, no. 6, article e0218423, 2019.
- L. K. Weaver, “Clinical practice. Carbon monoxide poisoning,” The New England Journal of Medicine, vol. 360, no. 12, pp. 1217–1225, 2009.
- B. M. Krause, S. Sabia, H. J. Manning, A. Singh-Manoux, and R. D. Sanders, “Association between major surgical admissions and the cognitive trajectory: 19 year follow-up of Whitehall II cohort study,” BMJ, vol. 366, article l4466, 2019.
- C. Wang, Y. Cui, J. Yang et al., “Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E ε4 genotype,” Biomarkers, vol. 20, no. 1, pp. 84–88, 2014.
- A. M. Saunders, W. J. Strittmatter, D. Schmechel et al., “Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease,” Neurology, vol. 43, no. 8, pp. 1467–1472, 1993.
- N. Mattsson, C. Groot, W. J. Jansen et al., “Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease,” Alzheimer's & Dementia, vol. 14, no. 7, pp. 913–924, 2018.
- P. Pastor, C. M. Roe, A. Villegas et al., “Apolipoprotein E ε4 modifies Alzheimer's disease onset in an E280A PS1 kindred,” Annals of Neurology, vol. 54, no. 2, pp. 163–169, 2003.
- S. Noguchi, K. Murakami, N. Yamada et al., “Apolipoprotein E genotype and Alzheimer's disease,” The Lancet, vol. 342, no. 8873, pp. 737-738, 1993.
- J. M. Farfel, L. Yu, P. L. De Jager, J. A. Schneider, and D. A. Bennett, “Association of APOE with tau-tangle pathology with and without β-amyloid,” Neurobiology of Aging, vol. 37, pp. 19–25, 2016.
- A. Drzezga, T. Grimmer, G. Henriksen et al., “Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease,” Neurology, vol. 72, no. 17, pp. 1487–1494, 2009.
- N. M. Wisdom, J. L. Callahan, and K. A. Hawkins, “The effects of apolipoprotein E on non-impaired cognitive functioning: A meta- analysis,” Neurobiology of Aging, vol. 32, no. 1, pp. 63–74, 2011.
- A. Serrano-Pozo, J. Qian, S. E. Monsell, R. A. Betensky, and B. T. Hyman, “APOEε2 is associated with milder clinical and pathological Alzheimer disease,” Annals of Neurology, vol. 77, no. 6, pp. 917–929, 2015.
- M. Fan, B. Liu, Y. Zhou et al., “Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults,” Neuroscience Letters, vol. 479, no. 3, pp. 332–336, 2010.
- J. Raber, Y. Huang, and J. W. Ashford, “ApoE genotype accounts for the vast majority of AD risk and AD pathology,” Neurobiology of Aging, vol. 25, no. 5, pp. 641–650, 2004.
- Y. Shi, Alzheimer’s Disease Neuroimaging Initiative, K. Yamada et al., “ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy,” Nature, vol. 549, no. 7673, pp. 523–527, 2017.
- Z. Lei, W. Yan, Z. Feng-chun, Z. Jin-rong, and L. Hongmei, “Combined detection of Apolipoprotein E ε4 allele and urinary AD7c-NTP in the early diagnosis of Alzheimer’s disease,” Journal of Apoplexy and Nervous Diseases, vol. 31, no. 7, pp. 585–589, 2014.
Copyright © 2020 Yuxia Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.